Efficacy and safety of thalidomide combined with VAD regimen in treatment of multiple myeloma: a Metaˉanalysis of Chinese literature
10.3760/cma.j.issn.1009ˉ9921.2019.05.006
- VernacularTitle:沙利度胺联合VAD方案治疗多发性骨髓瘤有效性与安全性的中文文献Meta分析
- Author:
Feifei LIU
1
;
Yan WANG
;
Xiaoyun LIN
;
Jianzhen SHEN
Author Information
1. 福建省血液病研究所 福建省血液病学重点实验室 福建医科大学附属协和医院血液内科
- Keywords:
Multiple myeloma;
Thalidomide;
VAD regimen;
Randomized controlled trial;
Metaˉanalysis
- From:
Journal of Leukemia & Lymphoma
2019;28(5):282-288
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the clinical efficacy and safety of thalidomide combined with VAD regimen (vincristine+epirubicin+dexamethasone) or VAD regimen alone in treatment of multiple myeloma (MM) by using metaˉanalysis. Methods Thalidomide combined with VAD regimen was selected as the experimental group and VAD regimen alone was selected as the control group. The literatures were searched from CNKI, Wanfang and VIP database. And then the inclusive literatures were further searched. Randomized controlled trials eligible to the exclusive criteria were extracted, and the quality was evaluated. Metaˉanalysis was conducted by using Stata14.0 software. Results A total of 17 studies and 940 patients were included. The experimental group had a higher total effective rate compared with the control group , and the difference was statistically significant ( RR＝ 1.41, 95% CI 1.30-1.59, P< 0.01). Meanwhile, the experimental group had a better efficacy in improving hemoglobin and deducing βˉmacroglobulin (MG), M protein and myeloma cells compared with the control group; however, the experimental group also had a worse gastrointestinal reaction, and the difference was statistically significant ( RR＝ 1.36, 95% CI 1.04-1.78, P＝ 0.024). Conclusion Thalidomide combined with VAD regimen in treatment of MM has a better clinical efficacy compared with VAD regimen alone, but it also has a worse adverse reaction.
